Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
äŒæ¥ã³ãŒãMYGN
äŒç€ŸåMyriad Genetics Inc
äžå Žæ¥Oct 06, 1995
æé«çµå¶è²¬ä»»è
ãCEOãRaha (Samraat S)
åŸæ¥å¡æ°2700
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 06
æ¬ç€Ÿæåšå°322 North 2200 West
éœåžSALT LAKE CITY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·84116
é»è©±çªå·18015843600
ãŠã§ããµã€ãhttps://myriad.com/
äŒæ¥ã³ãŒãMYGN
äžå Žæ¥Oct 06, 1995
æé«çµå¶è²¬ä»»è
ãCEOãRaha (Samraat S)